News | May 27, 2025
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Subscribe To Our Newsletter & Stay Updated
